- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
New Jersey pharma firm sees stocks fall
Author(s):
Berkeley Heights, N.J. - Pharmaceutical company Genta Inc., based here, announced recently that a phase 3 drug trial for the melanoma drug Genasense showed no statistically significant benefit compared with a placebo, reports news source Foxbusiness.com.
Berkeley Heights, N.J.
- Pharmaceutical company Genta Inc., based here, announced recently that a phase 3 drug trial for the melanoma drug Genasense showed no statistically significant benefit compared with a placebo, reports news source Foxbusiness.com.
Genta stock shares fell by more than 11 percent following the announcement.
The company also announced plans to cut staff by about 30 percent, adding that the cost savings should be enough to provide cash sufficient for continued operations into the second quarter of 2010.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
